Results 141 to 150 of about 23,468 (210)
Some of the next articles are maybe not open access.
Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?
Pharmacological Research, 2014Pitchai Balakumar
exaly +2 more sources
Clinical Pharmacology and Therapeutics, 1982
The kinetics of the antiplatelet drug dipyridamole were studied in six normal subjects (three men and three women) who were ages 22 to 34 yr old. Each received 20 mg IV and four also took a 50-mg oral dose. Blood samples were collected after each dose for a period of 3 days and concentrations of dipyridamole were measured by a sensitive and specific ...
C, Mahony +3 more
openaire +2 more sources
The kinetics of the antiplatelet drug dipyridamole were studied in six normal subjects (three men and three women) who were ages 22 to 34 yr old. Each received 20 mg IV and four also took a 50-mg oral dose. Blood samples were collected after each dose for a period of 3 days and concentrations of dipyridamole were measured by a sensitive and specific ...
C, Mahony +3 more
openaire +2 more sources
Echocardiography, 1992
Intravenous dipyridamole is a potent coronary vasodilator that has been extensively investigated over the past several years in the noninvasive assessment of patients with suspected coronary artery disease when exercise cannot be performed or is suboptimal.
R, Castello, A J, Labovitz
openaire +2 more sources
Intravenous dipyridamole is a potent coronary vasodilator that has been extensively investigated over the past several years in the noninvasive assessment of patients with suspected coronary artery disease when exercise cannot be performed or is suboptimal.
R, Castello, A J, Labovitz
openaire +2 more sources
Prognostic Value of High-Dose Dipyridamole Stress Myocardial Contrast Perfusion Echocardiography
Circulation, 2012 Nicola Gaibazzi +2 more
exaly +2 more sources
Pharmacokinetics of Dipyridamole
Acta Pharmacologica et Toxicologica, 1979AbstractDipyridamole, though originally introduced as a coronary vasodilator, has lately been increasingly investigated in the treatment of thromboembolic diseases because of its inhibitory influence upon blood platelet function. The compound is eliminated from the organism by hepatic biotransformation to the monoglucuronide, which almost exclusively ...
F, Nielsen-Kudsk, A K, Pedersen
openaire +2 more sources
Journal of Molecular Liquids, 2019
The solubility of dipyridamole was determined in five pure solvents (methanol, ethanol, 1-propanol, 2-propanol and 1-butanol) and three binary solvents (methanol + water, ethanol + water and 2-propanol + water) by gravimetric method from 293.15 K to 328 ...
Shuo Wang +6 more
semanticscholar +1 more source
The solubility of dipyridamole was determined in five pure solvents (methanol, ethanol, 1-propanol, 2-propanol and 1-butanol) and three binary solvents (methanol + water, ethanol + water and 2-propanol + water) by gravimetric method from 293.15 K to 328 ...
Shuo Wang +6 more
semanticscholar +1 more source
Dipyridamole in the Nephritides
American Journal of Therapeutics, 1998A summary is given of the properties of dipyridamole and of the trials at the time this article was written that indicate its potential efficacy in the therapy of glomerulonephritides.
openaire +2 more sources
International journal of clinical practice, 1997
In 1988, an optimal antiplatelet regimen for secondary stroke prevention remained to be defined. We undertook a randomised, placebo‐controlled, double‐blind trial to investigate the safety and efficacy of low‐dose acetylsalicylic acid (ASA), modified ...
C. Forbes
semanticscholar +1 more source
In 1988, an optimal antiplatelet regimen for secondary stroke prevention remained to be defined. We undertook a randomised, placebo‐controlled, double‐blind trial to investigate the safety and efficacy of low‐dose acetylsalicylic acid (ASA), modified ...
C. Forbes
semanticscholar +1 more source